Figure 1
From: Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
Synergistic interaction of c-MET and Bcl-2/Bcl-xL inhibition in established and stem-like GBM cells. (A) LN229, U87 and NCH644 stem-like GBM cells were treated with increasing concentrations with c-MET inhibitor, Crizotinib, and analyzed for cellular viability (3d). Shown are means and SD. Non-linear regression analysis was applied to calculate IC50 values. n = 3 (B) The same cell lines as in A were treated with suboptimal dosages of ABT263, Crizotinib or the combination and analyzed for cellular viability after 72 h. Shown are means and SD. n = 3 (C,D) Based on viability assays, CI values were calculated, using the software CompuSyn (ComboSyn, Inc., Paramus, NJ, U.S.A.). CI values below 1 indicate synergistic interactions, whereas values above 1 show antagonism (CI values vs. fraction affected). Isobolograms are further highlighting the synergistic interaction between ABT263 and Crizotinib. The applicable concentrations (in μM) for the used compounds are shown on the right side of the figure. A: ABT263, C: Crizotinib.
